Bought
Maintained
Sold
Other funds holding ALT
UBS AM's ALT Position: Q3 2026 in Review
UBS AM reduced its Altimmune (ALT) stake by 93% in Q3 2026, selling an estimated $11.8K and leaving 298 shares worth $852. The position accounts for ﹤0.01% of the portfolio, ranked #4145.
UBS AM first reported a position in ALT in Q4 2022 and has held it in 13 quarters since. The position peaked at $900K in Q4 2022. 155 funds tracked by Wall St. Rank hold ALT as of Q3 2026.
- UBS AM held 298 shares of Altimmune worth $852 as of Q3 2026.
- UBS AM sold 3,856 Altimmune shares in Q3 2026, an estimated $11.8K.
- Altimmune made up ﹤0.01% of UBS AM's portfolio in Q3 2026, its #4145 holding.
- UBS AM first reported a position in Altimmune in Q4 2022 and has held it in 13 quarters since.
- UBS AM's Altimmune position peaked at $900K in Q4 2022.
- 155 funds tracked by Wall St. Rank held Altimmune as of Q3 2026.
Based on UBS AM's 13F filing for Q3 2026, filed 16 Nov 2026.